title: XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
source: Yahoo
date: 2025-10-19
url: https://finnhub.io/api/news?id=f4ca7f9aeac32df9ce5886fae228ca1af8abef9e81db1b708071fbed6fc3dc10
NEW YORK & NORTHBROOK, Ill., October 19, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) a
